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Abstract
Background: Haploinsufficiency at the PAX6 locus causes aniridia, a panocular eye condition
characterized by iris hypoplasia and a variety of other anterior and posterior eye defects leading to
poor vision. This study was performed to identify novel PAX6 mutations that lead to familial aniridia
in Indian patients.
Methods: Genomic DNA was isolated from affected individuals (clinically diagnosed aniridia) from
nine unrelated aniridic pedigrees, unaffected family members, and unrelated normal controls. The
coding regions of PAX6 were amplified and subjected to single strand conformation polymorphism
(SSCP) gel analysis, and direct cloning and sequencing.
Results: SSCP band shifts, indicative of DNA base pair mutations, were observed in five of these
unrelated families. Four mutations were shown to be previously unreported insertion or deletions
in PAX6, leading to frameshifts. These new mutations were c.1174delTG (in exon 10), c.710delC
(exon 6), c.406delTT (exon 5) and c.393insTCAGC (exon 5). The other nonsense mutation, a
transition (c.1080C>T) in exon 9, has been reported previously as a mutation hotspot for PAX6 in
other ethnic pedigrees. All mutant alleles transmitted through aniridic individuals in each family.
Conclusion: These new deletions and an insertion create frameshifts, which are predicted to
introduce premature termination codons into the PAX6 reading frame. The genetic alterations
carried by affected individuals are predicted to lead to loss-of-function mutations that would
segregate in an autosomal dominant manner to subsequent generations. This is the first report of
the 'hotspot' c.1080C>T transition from Indian families.
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Background
Congenital absence of the iris is known as aniridia in
humans. Aniridia is mostly a panocular defect leading to
anterior and posterior segment defects that are associated
with isolated cataracts, macular hypoplasia, keratitis, and
Peter's anomaly [1]. One third of cases are sporadic and
two thirds are familial with an autosomal dominant
mode of inheritance with high penetrance [2]. PAX6, from
chromosome band 11p13, was identified as the candidate
gene for aniridia by positional cloning [3]. PAX6 is widely
expressed in the developing eye and is one of the master
control genes in eye development. Molecular genetics
studies have revealed that autosomal dominant aniridia
results from many possible mutations in the PAX6 gene
[4-7]. The PAX6  gene spans 22 kb and consists of 14
exons. The translation initiation codon is in exon 4 and
the termination codon is in exon 13 [4]. The human PAX6
gene has paired box and homeobox motifs that encode a
highly conserved protein of 422 amino acids among
metazoans. The paired domain and the homeodomain
are DNA binding domains, and are separated by a linker
segment (LNK) and followed by a C-terminal region rich
in proline, serine and threonine (PST). PAX6 functions as
a transcription factor to regulate the expression of other
genes during embryogenesis and in the adult eye [8].
Mutations in the PAX6 have so for been described in spo-
radic cases from India [6,7], but there was no previous
report on mutations in Indian familial aniridia. We there-
fore present an analysis of five Indian pedigrees out of
nine with hereditary aniridia demonstrating four novel
mutations and one previously reported nonsense genetic
alteration of PAX6.
Methods
Clinical evaluation and proband selection
The study protocol adhered to the tenets of the Declara-
tion of Helsinki. After providing informed consent, nine
unrelated clinically diagnosed inherited aniridia families
(ANF1 to ANF9) with their available unaffected members
and 60 healthy non-aniridic unrelated normal controls
were recruited for this study. Ophthalmic specialists
selected these families in the first instance because of iris
absence, and classical aniridia was confirmed by the pres-
ence of secondary eye defects consistent with aniridia, and
no contraindications. Examination included slit lamp,
gonioscopy, intraocular pressure measurement, and
biomicroscopy. Peripheral blood samples were collected
for isolation of total genomic DNA by salt precipitation
from probands, affected, unaffected family members, and
normal controls.
Mutation screening and sequence analysis
Exons 4–13 of the human PAX6  gene were amplified
using previously described primers [4] in a 20 μl reaction
mixture containing 100 ng genomic DNA, 100 pM of each
primer, 1X PCR buffer (Promega, USA) and 0.5 U of Taq
DNA polymerase (Promega, USA). PCRs were carried out
in a MJ Research thermocycler for 35 cycles. PCR condi-
tions were 1 minute at 95°C for denaturation, 1 minute at
58°C for primer annealing and 10 minutes at 72°C for
primer extension. The amplified PCR products showing a
single band of the correct size were stored at -20°C before
electrophoretic analysis. For single-strand conformation
polymorphism (SSCP) analysis, approximately 6 μl of the
amplified DNA was mixed with 4 μl of denaturing dye
(95% formamide, 10 mM NaOH) and run on a 10% poly-
acrylamide gel with or without 2.5% glycerol. Electro-
phoresis was carried out for 6 hours at 800 V. The gels
were stained with silver nitrate as described previously [6].
Based on the mobility shifts seen on the SSCP gel, exons
containing potential mutations were re-amplified and the
PCR products were purified by excising the desired band
from the agarose gel and eluting using a QIA quick gel
extraction kit (QIAGEN Gmbh, Germany). PCR products
were either sequenced directly or cloned into pGEM-T
(Promega USA). The superimposed mutant PCR products
were amplified, ligated, then transformed into E. coli
DH5α and plated onto LB agar medium containing amp-
icillin. Transformed colonies were patched on a different
plate for the isolation of plasmids. About 10 individual
colonies were picked from each ligation and then plas-
mids were isolated by alkaline lysis. These plasmids were
checked by restriction enzyme digestion and used as tem-
plates in PCR reactions for amplification of the insert. The
mutants were detected by allele specific clones
The PCR products were sequenced on Applied Biosystems
(ABI) model 3730 automated sequencer (Microsynth,
Switzerland) using PCR primers from published literature
[4] or universal primers for pDrive (QIAGEN, Germany).
Digestion
Ten microliters of the mutant and normal PCR products
were digested in a reaction mixture containing 1X buffer
and 10 U of appropriate restriction enzyme (Fermentas,
Germany). The reaction was incubated at 37°C for 2
hours and the products were visualized on a 2.5% agarose
gel.
PAX6 cDNA numbering
PAX6 cDNA sequences used and mutations were anno-
tated according to the PAX6 Allelic Variant Database [9].
The coding region runs from base 363 (in exon 4) to base
1628 (in exon 13). The PST region extends from base
1169 to base 1628.
Results
We screened for PAX6 mutations in genomic DNA from
nine Indian pedigrees with familial aniridia in which
more than one person was affected. The probandsBMC Ophthalmology 2006, 6:28 http://www.biomedcentral.com/1471-2415/6/28
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recruited in this study have typical bilateral aniridia with
primary complications. The clinical information on the
affected members is given in Table 1. Exons 4–13 of PAX6
(encompassing the entire coding region) were amplified
from affected and unaffected individuals, as well as unre-
lated unaffected controls. PCR products were used for sin-
gle-strand conformation polymorphism (SSCP) analysis.
In five out of nine families, the affected members showed
unusual band shifts on the 10% polyacrylamide gel. These
shifts are caused by mono-allelic base sequence changes.
Mutant alleles identified by SSCP were cloned and
sequenced to determine the nucleotide changes underly-
ing the aniridic phenotype. All mutant alleles are summa-
rised in Table 2.
Family ANF6: mutation c.1080C>T
The mother and her daughter were affected with aniridia
in the two-generation family ANF6. Sequencing revealed
a transition in exon 9, c.1080C>T in both affected individ-
uals. The unaffected family members showed normal alle-
les of PAX6. The C>T substitution at codon 240 converts
an arginine codon (CGA) to a termination codon (TGA)
(R240X). The mutation was predicted to remove an AvaI
site. A 206 bp band around the mutation was amplified
and digested with AvaI restriction enzyme to reconfirm
the presence of the mutation in exon 9 of PAX6. The
digested product of the normal allele yielded 131 bp and
75 bp fragments on a 1.5% agarose gel in unaffected indi-
viduals whereas 206bp, 131bp, and 75bp fragments were
obtained from individuals heterozygous for the mutant
allele (Fig. 1A). This mutation has been reported previ-
ously in various ethnic populations but this is the first
report from familial aniridia in India [5,6].
Family ANF2: novel mutation c.1174delTG
[Genbank:DQ251040]
Affected individuals from the three-generation family
ANF2 showed bands with altered mobility shift on SSCP
gels and were shown by sequencing to be heterozygous for
the mutation c.1174delTG at codon 271 in exon 10 (Fig.
2A, C). The affected aniridic mother passed the mutation
onto two children. This deletion leads to a frameshift,
alters a leucine residue (codon 271) and creates a prema-
ture termination codon 12 residues downstream. The con-
formations observed both in genomic DNA and the
cloned PCR products showed the same profiles (Fig. 2A,
B). The mutation was predicted to alter a DdeI site in exon
10 and the mutation was reconfirmed by DdeI restriction
of PCR products from both in unaffected controls and in
mutants. The wild-type alleles of unaffected individuals
and unrelated normal controls showed two bands, 160 bp
and 83 bp, whereas DNA from the affected individuals
yielded 243 bp, 160 bp and 83 bp bands (Fig. 2D), con-
firming the loss of the DdeI restriction site on one allele of
affected individuals in this family.
Family ANF7: novel mutation c.710delC
[Genbank:DQ251039]
The PCR products of affected individuals from the two-
generation family ANF7 (Fig. 2E) showed aberrant band-
ing patterns on SSCP analysis. Sequencing indicated a
deletion mutation c.710delC in all the affected individu-
als in this family. The conformation profiles of genomic
PCR-SSCP and the cloned allele-specific PCR products
showed the same pattern (Fig. 2E, F). Deletion of the sin-
gle cytosine residue (Fig. 2I) is predicted to lead to a
frameshift at codon 116 (asparagine) of exon 6 (Fig 2I)
and lead to a stop codon in exon 7 within the paired
domain. The PCR product of the unaffected father showed
a wild-type allele of PAX6 (Fig. 2H).
Family ANF9: novel mutation c.406delTT
[Genbank:DQ251038]
In the two generation consanguinous family ANF9 (Fig.
3A), an obvious bandshift on the SSCP gel was seen
which, on sequencing, proved to be due a two base pair
deletion at c.406delTT that disrupts a phenylalanine at
codon 15 in the paired domain (Fig. 3B). The mutation
resulted in frameshift in exon 5 and creates the stop codon
at exon 6 (40 codons distal to the mutation). Normal alle-
les were found in unaffected family members (Fig 3C).
Family ANF8: novel mutation c.393ins5
[Genbank:DQ251037]
The mutation in another three generation family ANF8
was originally detected by SSCP in exon 5 (Fig. 4A, B) of
the paired domain and was further analyzed by sequenc-
ing the PCR product of affected individuals and unaf-
fected relatives from the family. The DNA sequence of the
PCR product of affected heterozygous individuals showed
a 5 base pair insertion duplication (TCAGC) at c.393ins5
(codon 11) (Fig 4C, D). This results in a frameshift muta-
tion at a leucine residue, which produces a premature ter-
mination codon 20 codons distal to the mutation
location, in exon 5 within the paired domain. The male
ANF8-1 had sudden loss of vision at age 11 and anterior
segment examination revealed bilateral microcornea with
aniridic keratopathy. Another affected 8-year old female
ANF8-3 also had microcornea with post polar cataract in
the right eye.
Five mutations in the coding regions have therefore been
documented in the family study, in which we have identi-
fied four novel mutant PAX6 alleles in Indian familial ani-
ridic patients.Discussion
Most familial aniridia patients have mutations within PAX6 that are dominantly inher-
ited with high penetrance. Sporadic cases are likely to have de novo mutations in PAX6,
and expected to be transmitted to the next generation in an autosomal dominant fashion.
In this study, we observed several novel PAX6 mutations in familial aniridia. Affected
family members in at least two generations carry the mutant alleles.
SSCP is an easy, but perhaps inefficient method to screen for mutations in genomic DNA.
In this study, five mutations were found in PAX6 in affected members from nine unre-
lated families with inherited aniridia. All the mutations were identified initially based on
aberrant bands on SSCP gels that differed from the normal allelic patterns shown by unaf-
fected family members. Each mutation was only found in affected individuals.
Many mutations in PAX6 generating premature termination codons have been previously
reported [10] and are deposited in the Human PAX6 Allelic Variant Database [9]. A
c.1080C>T change (R240X), identical to that in our family ANF6, that was identified
recently in a Thai study also showed complete aniridia with nystagmus, strabismus and
foveal hypoplasia [10] c1080C>T has been reported several times previously in other eth-
nic groups and appears to represent a hotspot of PAX6 mutation, perhaps due to methyl-
ated cytosine deamination. The c.393insTCAGC insertion in ANF8-1 is novel, but a
c.395delC mutation with familial aniridia was previously reported which lies in same
codon of PAX6 but two base pairs down [12].
The mutant mRNAs predicted by this study are likely to be detected by RNA surveillance
and degraded by nonsense-mediated decay [13,14], and hence we predict that they will
all represent loss-of-function mutations.
Table 1: Clinical information of familial aniridia patients
Patient Best Vision Refractive Error Nystagmus Keratopathy Iris Cataract Glaucoma Fovea Hypoplasia Macular Hypoplasia Treatment
Number [Sex] (Age) Medical 
treatment
Surgical 
treatment
RL R L R L R L R LRL R L R L R L
ANF2-1 F (5) CF 6/60 - -5.0-2.0 + + - R + - + + + + - - + + 1,2 1
ANF2-3 M (11) PL 5/60 - +10 + + - R - + - + + + - - - + - 1,2
ANF2-2 F (28) PL 3/60 -2.0 - + + - A - - - - + + - - - - -
ANF6-1 F (10) 4/60 6/36 -2.0 - + + + A + + - - + + + + - - - -
ANF6-2 F (24) 3/60 3/60 +11 +11.5 + + + A + - - - + + - + - - - -
ANF7-1 M (0.5) NA NA - - + - - R - - - - + + - - - - - -
ANF7-2 F (22) 6/18 PL +11 - + - + A + - - - + + - - - - 2 -
ANF9-1 F (5) 6/24 6/24 -4.0 -4.0 + - - A - - - - + + - - - - - -
ANF9-2 M (39) 3/60 3/60 -2.0 -2.5 + - - R + + - - + + - - - - - -
ANF8-1 M (12) PL PL - - + + + A + + - - + + - - - - - -
ANF8-2 M (45) 6/36 6/36 +1.5 +1.5 + - - A + - - - + + - - - - - -
ANF8-3 F (8) PL PL - - + - - A + - - - + + - - - - - -
Key: PL, perception of light; CF, counting fingers; A, absent; R, remnant; NA, not applicable; 1, trabeculectomy: 2, cataract surgery
Table 2: Summary of genetic variation in familial aniridic patients
S No Systematic Name Codon Exon/Intron Domain Common Name patient ID Type of Mutation Interpretation Gene bank 
Accession No.
01 c.1080 C>T R240X exon 9 Homeodomain ANF/6-1 female Premature termination Arginine to stop codon --
03 c.1174del TG 271 exon 10 PST region ANF/2-1 female Deletion Novel mutation DQ251040
05 c.710del C 116 exon 6 Paired domain ANF/7-1 male Deletion Novel mutation DQ251039
07 c.406delTT 15 exon 5 Paired domain ANF9-1female Deletion Novel mutation DQ251038
09 c.393ins5 11 exon 5 Paired domain ANF8-1 male Insertion Novel mutation DQ251037BMC Ophthalmology 2006, 6:28 http://www.biomedcentral.com/1471-2415/6/28
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Conclusion
Our genetic analysis provides further examples of PAX6
haploinsuffiency leading to aniridia. We report four novel
frameshift mutations and one nonsense mutation in
Indian aniridic pedigrees. This is the first genetic analysis
of familial aniridia in Indian populations and contributes
to our understanding of the relationship between PAX6
genotype and ocular phenotype.
Mutation analysis of two unrelated families, ANF2 and ANF7 Figure 2
Mutation analysis of two unrelated families, ANF2 
and ANF7. A. SSCP gel stained with silver nitrate showing 
unaffected members (2–4, 2–5) and the unusual band shift in 
affected members (2–1, 2–2), and normal bands in an unre-
lated unaffected control (lane 1). B. Identical banding pat-
terns were obtained from the cloned mutant (M) and the 
genomic mutant (G) DNA on silver stained polyacylamide 
gels. N represents normal alleles. C. Three generation ani-
ridic pedigree showing the affected and unaffected members 
and sequencing results of cloned mutant alleles showing the 
mutant (c.1174delTG) and wild-type alleles of exon 10. D. 
Restriction digestion analysis: PCR products of the family 
ANF2 showed heterozygosity (2–1, 2–2) for the mutant 
allele (243 bp, 160 bp and 83 bp). The wild type shows bands 
at 160 bp and 83 bp (2–4, 2–5, UN) when digested with DdeI. 
UN represents an unaffected control. UD represents undi-
gested PCR product of exon 10. E. Polyacrylamide gel show-
ing the bandshift in affected members (7–1, 7–2) but no shift 
on normal family members or unrelated controls (UN) (UN, 
7–3, 7–4) of family ANF7. F. Allele specific clones were iso-
lated to confirm the correct clone (M) compared with 
genomic PCR (G). G. The pedigree showing the two-genera-
tion aniridic family (filled-affected, unfilled-unaffected). H. 
Sequence of the unaffected father showing wild type PAX6. I. 
Sequencing of cloned alleles revealed the presence of single 
cytosine residue deletion in exon 6 in the mutants.
Detection of a nonsense mutation (R240X) in the two-gener- ation family ANF6 Figure 1
Detection of a nonsense mutation (R240X) in the 
two-generation family ANF6. A- Pedigree showing the 
affected (dark filled) and unaffected (unfilled) family members. 
Cloned gPCR product digested with AvaI restriction enzyme 
confirms heterozygosity for the mutation in affected individu-
als (band sizes 206 bp, 131 bp, 75 bp in lane 2, 3) whereas the 
unaffected members carry only normal alleles with digested 
bands at 131 bp and 75 bp (lane 1 and 4). The unrelated nor-
mal control is shown on the left (UN). Undigested PCR 
product is on the right (UD). B- Normal chromatogram of 
PAX6 shows the presence of CGG (arginine) in exon 9. C- 
Direct sequencing of the genomic PCRs of the affected 
mother and (D) affected proband showing the presence of 
mutation, X-represents stop codon.BMC Ophthalmology 2006, 6:28 http://www.biomedcentral.com/1471-2415/6/28
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